Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760211 | 0.76 | KCNH2 (0.37) | KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL21145423 | 0.74 | ALDH1A1 (0.33) | KCNH2ALDH1A1 | |
| SCHEMBL26586427 | 0.73 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL3295512 | 0.72 | KCNH2 (0.42) | KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3817668 | 0.71 | ALDH1A1 (0.46) | KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL26586530 | 0.69 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL29428931 | 0.67 | CA1 (0.45) | KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3820431 | 0.67 | CA1 (0.45) | KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL26586642 | 0.67 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL11553756 | 0.66 | KCNH2 (0.43) | KCNH2KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181014-B1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | GENENTECH, INC. | 2005-09-15 | — | — | US | disclosed |
| US-6927227-B2 | Heterocyclic containing biphenyl aP2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | ROBL JEFFREY A (US) | 2003-10-23 | — | — | US | disclosed |
| US-6548529-B1 | AP2 (adipocyte fatty binding protein); biphenyl-substituted pyrazoles of given formula; treating diabetes and related diseases; mixtures with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | VCAM1, CD58, ITGB8 | KCNH2 2520/4885KDM4E 3946/4885ALDH1A1 280/4885 |
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | AP2B1, AP2A2, AP2A1 | KCNH2 2263/4885KDM4E 3079/4885ALDH1A1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.